Lindbrook Capital, LLC Karuna Therapeutics, Inc. Transaction History

Lindbrook Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$161.01 - $317.85 $19,643 - $38,777	122 Added 105.17%	238 $75,000
Q3 2023 Oct 25, 2023	BUY	$164.66 - $218.08 $4,281 - $5,670	26 Added 28.89%	116 $19,000
Q2 2023 Jul 28, 2023	SELL	$176.32 - $240.22 $3,702 - $5,044	-21 Reduced 18.92%	90 $19,000
Q1 2023 Apr 26, 2023	SELL	$161.33 - $204.36 $4,678 - $5,926	-29 Reduced 20.71%	111 $20,000
Q4 2022 Jan 24, 2023	SELL	$191.53 - $236.82 $14,939 - $18,471	-78 Reduced 35.78%	140 $0
Q3 2022 Nov 10, 2022	BUY	$123.79 - $277.42 $5,075 - $11,374	41 Added 23.16%	218 $49,000
Q2 2022 Aug 01, 2022	SELL	$93.97 - $143.33 $6,108 - $9,316	-65 Reduced 26.86%	177 $22,000
Q1 2022 Apr 21, 2022	SELL	$98.9 - $132.37 $33,428 - $44,741	-338 Reduced 58.28%	242 $31,000
Q4 2021 Jan 18, 2022	BUY	$110.64 - $159.4 $64,171 - $92,452	580 New	580 $76,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.